Protocadherin alpha 14 (PCDHA14)

Protocadherin alpha 14 (PCDHA14) is a member of the clustered protocadherin alpha gene family, which is primarily expressed in the nervous system and contributes to the molecular diversity of neuronal cell-surface proteins required for the establishment and maintenance of specific neural connections[4][6][9]. PCDHA14 shares the typical structure of protocadherins: an extracellular domain with six cadherin repeats, a transmembrane region, and an intracellular cytoplasmic tail distinct from classical cadherins. In mice, the alpha cluster contains 14 variable exons encoding individual isoforms, each driven by an independent promoter[2][3][4]. However, PCDHA14 in humans is annotated as a pseudogene, meaning it does not encode a functional protein[8]. Some of its aliases ("protocadherin gamma subfamily A 14 pseudogene," "CNR3") reflect prior misannotation or historical naming conventions, but current genomic evidence indicates PCDHA14 does not produce a protein and thus is not a therapeutic target[8]. True functional protocadherin alpha isoforms (e.g., PCDHA1–13) participate in cell adhesion, intracellular signaling, and synaptic specificity, but PCDHA14 itself lacks this functional capacity. Summary of Key Issues: - PCDHA14 is a pseudogene and not a functional protein target or therapeutic receptor. - Some listed aliases also map to other genes or obsolete nomenclature, adding confusion. - No biomarkers, drugs, safety concerns, or mechanism of action are relevant for this entry, as it is not a druggable or disease-modifying molecule. For structured data applications, flag this entry as not a valid molecular therapeutic target, and consider excluding or separately annotating pseudogenes from canonical target lists[8].

Other names

CNR3CRNR3PCDH-PSI4CNRN3CNRS3cadherin-related neuronal receptor 3protocadherin gamma subfamily A 14 pseudogene

Not applicable (no therapeutic agents with validated mechanism of action for PCDHA14)